# NAD+ dosage & reconstitution (1000 mg vial)

NAD+ dosage: calculations for a 1000 mg vial use the same amounts described in the literature. Adding 3 mL of bacteriostatic water produces 333.33 mg/mL, so each U-100 unit contains 3333 mcg.

- **Vial contents:** 1000 mg NAD+
- **Final volume:** 3 mL
- **Concentration:** 333.33 mg/mL
- **One U-100 unit:** 3333 mcg in 0.01 mL

## Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing

### Standard / Gradual Titration Approach (3 mL = ~333.33 mg/mL)

| Week / phase | Daily dose | Units per injection (mL) |
|---|---|---|
| Week 1 | 50 mg (50000 mcg) | 15 units (0.15 mL) |
| Week 2 | 75 mg (75000 mcg) | 22.5 units (0.23 mL) |
| Weeks 3–8 | 100 mg (100000 mcg) | 30 units (0.30 mL) |
| Weeks 9–12 | 100 mg (100000 mcg) | 30 units (0.30 mL) |
| Weeks 13–16 | 100 mg (100000 mcg) | 30 units (0.30 mL) |

Frequency: Once daily, subcutaneously, at a consistent time.

### Reconstitution Steps

1. Draw 3 mL of bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid shaking to prevent foaming.
3. Gently swirl or roll until fully dissolved (clear solution).
4. Label with the reconstitution date and refrigerate at 2–8 °C, protected from light; use within 4 weeks.

Important: this guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

## U-100 Conversion Table

| U-100 units | Volume | Contains | Yield per vial |
|---|---|---|---|
| 2 | 0.02 mL | 6.66667 mg (6667 mcg) | 150 injections |
| 5 | 0.05 mL | 16.6667 mg (16667 mcg) | 60 injections |
| 10 | 0.10 mL | 33.3333 mg (33333 mcg) | 30 injections |
| 20 | 0.20 mL | 66.6667 mg (66667 mcg) | 15 injections |
| 30 | 0.30 mL | 100 mg (100000 mcg) | 10 injections |
| 50 | 0.50 mL | 166.667 mg (166667 mcg) | 6 injections |
| 100 | 1.00 mL | 333.333 mg (333333 mcg) | 3 injections |

## Supplies Needed

**NAD+ vials (1000 mg each)**
- Standard / Gradual Titration Approach, 12 weeks: Minimum 8 vials (7875 mg required).
- Standard / Gradual Titration Approach, 24 weeks: Minimum 17 vials (16275 mg required).

**U-100 syringes (1 mL)**
- Standard / Gradual Titration Approach, 12 weeks: 84 new syringes for 84 injections.
- Standard / Gradual Titration Approach, 24 weeks: 168 new syringes for 168 injections.

**Bacteriostatic water**
- Standard / Gradual Titration Approach, 12 weeks: 24 mL total (3 mL per vial) → 8 × 3 mL vials.
- Standard / Gradual Titration Approach, 24 weeks: 51 mL total (3 mL per vial) → 17 × 3 mL vials.

**Alcohol swabs**
- Standard / Gradual Titration Approach, 12 weeks: 168 minimum; one box of 100 does not cover the calculation.
- Standard / Gradual Titration Approach, 24 weeks: 336 minimum; one box of 100 does not cover the calculation.

## Storage Instructions

- Lyophilized (unopened): −20 °C for long-term storage; 2–8 °C if used within weeks. Protected from light.
- Reconstituted: 2–8 °C, do not freeze. Use within the documented period (typically up to 4 weeks with bacteriostatic water).
- Handling: do not shake; avoid temperature cycling; label with date and concentration.
- Discard: cloudy solutions, particulates or expired preparations are discarded.

## How This Works

NAD+ acts simultaneously as an enzymatic cofactor and as a substrate in multiple pathways: Sirtuin activation (SIRT1-7): Sirtuins are NAD+-dependent deacetylases that regulate key processes: mitochondrial biogenesis, oxidative stress response, longevity, lipid metabolism, and telomeric integrity maintenance. Without available NAD+, sirtuins do not function. DNA repair via PARP: Poly-ADP-ribose polymerases (PARP) consume NAD+ during DNA break repair. When there is significant genomic damage, PARPs rapidly sequester NAD+, which can deplete the pools available for other functions. ATP Production: NAD+ is the main electron acceptor in the Krebs cycle (TCA) and in fatty acid beta-oxidation. Its availability directly determines the cell's capacity to generate ATP from glucose or fat. cADPR and NAADP signaling: NAD+ is a precursor of second messengers that regulate intracellular calcium release, critical for muscle function, neurotransmission, and immune response.

## References

1. Verdin E. NAD+ in aging, metabolism, and neurodegeneration. Science. 2015;350(6265):1208-1213.
2. Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metab. 2018;27(3):529-547.
3. Yoshino J, Baur JA, Imai SI. NAD+ intermediates: the biology and therapeutic potential of NMN and NR. Cell Metab. 2018;27(3):513-528.
4. Imai S, Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 2014;24(8):464-471.
5. Mills KF, Yoshida S, Stein LR, et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metab. 2016;24(6):795-806.

---
Source: https://protocolopeptidos.com/en/compuestos/nad-plus-1000mg · Important: this guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.